PURPOSE OF REVIEW: This review will provide an update on the most recent clinical developments in immuno-oncology in advanced gynecologic cancers and will also highlight ongoing studies in this field. RECENT FINDINGS: Although immune checkpoint blockade (ICB) therapy is rapidly altering the treatment landscape in a myriad of solid tumors, the efficacy of ICB therapy with antibodies directed against CTLA-4, PD-1, and PD-L1 in advanced gynecologic cancers has been limited. The exception has been the PD-1 inhibitor pembrolizumab in microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) advanced endometrial cancers, highlighted by the recent conditional approval of pembrolizumab in recurrent/metastatic PD-L1-positive cervical cancers and the accelerated approval of pembrolizumab and lenvatinib in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) advanced endometrial cancer. The discovery of novel, rational ICB combinatorial approaches in advanced gynecologic cancers is highly warranted. SUMMARY: Recent advances in the genomic characterization of gynecologic malignancies have informed clinical trial design. However, improved molecular and immunophenotypic biomarkers to more accurately identify patients who will most benefit from immunotherapeutic approaches are urgently needed. This is especially critical as we attempt to integrate immune-oncology agents, chemotherapy, targeted therapy, and radiation therapy in the management of gynecologic cancers.
PURPOSE OF REVIEW: This review will provide an update on the most recent clinical developments in immuno-oncology in advanced gynecologic cancers and will also highlight ongoing studies in this field. RECENT FINDINGS: Although immune checkpoint blockade (ICB) therapy is rapidly altering the treatment landscape in a myriad of solid tumors, the efficacy of ICB therapy with antibodies directed against CTLA-4, PD-1, and PD-L1 in advanced gynecologic cancers has been limited. The exception has been the PD-1 inhibitor pembrolizumab in microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) advanced endometrial cancers, highlighted by the recent conditional approval of pembrolizumab in recurrent/metastatic PD-L1-positive cervical cancers and the accelerated approval of pembrolizumab and lenvatinib in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) advanced endometrial cancer. The discovery of novel, rational ICB combinatorial approaches in advanced gynecologic cancers is highly warranted. SUMMARY: Recent advances in the genomic characterization of gynecologic malignancies have informed clinical trial design. However, improved molecular and immunophenotypic biomarkers to more accurately identify patients who will most benefit from immunotherapeutic approaches are urgently needed. This is especially critical as we attempt to integrate immune-oncology agents, chemotherapy, targeted therapy, and radiation therapy in the management of gynecologic cancers.
Authors: Hyun Cheol Chung; Willeke Ros; Jean-Pierre Delord; Ruth Perets; Antoine Italiano; Ronnie Shapira-Frommer; Lyudmila Manzuk; Sarina A Piha-Paul; Lei Xu; Susan Zeigenfuss; Scott K Pruitt; Alexandra Leary Journal: J Clin Oncol Date: 2019-04-03 Impact factor: 44.544
Authors: Joyce F Liu; Christina Herold; Kathryn P Gray; Richard T Penson; Neil Horowitz; Panagiotis A Konstantinopoulos; Cesar M Castro; Sarah J Hill; Jennifer Curtis; Weixiu Luo; Ursula A Matulonis; Stephen A Cannistra; Don S Dizon Journal: JAMA Oncol Date: 2019-12-01 Impact factor: 31.777
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: David B Page; Michael A Postow; Margaret K Callahan; James P Allison; Jedd D Wolchok Journal: Annu Rev Med Date: 2013-10-30 Impact factor: 13.739
Authors: Panagiotis A Konstantinopoulos; Steven Waggoner; Gregory A Vidal; Monica Mita; John W Moroney; Robert Holloway; Linda Van Le; Jasgit C Sachdev; Eloise Chapman-Davis; Gerardo Colon-Otero; Richard T Penson; Ursula A Matulonis; Young Bae Kim; Kathleen N Moore; Elizabeth M Swisher; Anniina Färkkilä; Alan D'Andrea; Erica Stringer-Reasor; Jing Wang; Nathan Buerstatte; Sujata Arora; Julie R Graham; Dmitri Bobilev; Bruce J Dezube; Pamela Munster Journal: JAMA Oncol Date: 2019-08-01 Impact factor: 31.777
Authors: Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: Oncotarget Date: 2016-03-22
Authors: Amit Atwal; Tristan Snowsill; Marcus Cabrera Dandy; Thomas Krum; Claire Newton; Dafydd Gareth Evans; Emma J Crosbie; Neil A J Ryan Journal: Int J Cancer Date: 2022-07-06 Impact factor: 7.316